Nathalie Asherie

Jerusalem, JM, Israel

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

B cell Maturation Antigen Targeted Chimeric Antigen Receptor T Cell Therapy for Refractory Systemic Lupus Erythematosus and Systemic Sclerosis.

B cell Maturation Antigen Targeted Chimeric Antigen Receptor T Cell Therapy for Refractory Systemic Lupus Erythematosus and Systemic Sclerosis.

Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: March 11, 2026

Viral Reactivation in Multiple Myeloma Patients Receiving Anti-BCMA Chimeric Antigen Receptor T-Cell Therapy.

Viral Reactivation in Multiple Myeloma Patients Receiving Anti-BCMA Chimeric Antigen Receptor T-Cell Therapy.

Journal: International journal of molecular sciences
Published: January 20, 2026

High Rate of Cytokine Release Syndrome-Related Coagulopathy with Low Incidence of Bleeding and Thrombosis in Patients Treated with B-Cell Maturation Antigen (BCMA)-Targeted Chimeric Antigen Receptor T-Cells (CAR-T).

High Rate of Cytokine Release Syndrome-Related Coagulopathy with Low Incidence of Bleeding and Thrombosis in Patients Treated with B-Cell Maturation Antigen (BCMA)-Targeted Chimeric Antigen Receptor T-Cells (CAR-T).

Journal: Cancers
Published: September 21, 2025

A single-cell atlas of multiple myeloma defines malignant archetypes and proliferative states.

A single-cell atlas of multiple myeloma defines malignant archetypes and proliferative states.

Journal: Nature genetics
Published: August 17, 2025

Efficacy and Safety of Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis.

Efficacy and Safety of Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 09, 2024

Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma.

Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma.

Journal: Blood advances
Published: February 20, 2024

Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma.

Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 15, 2024

Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?

Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?

Journal: Cancers
Published: June 06, 2023

Early lymphocyte collection for anti-CD19 CART production improves T-cell fitness in patients with relapsed/refractory diffuse large B-cell lymphoma.

Early lymphocyte collection for anti-CD19 CART production improves T-cell fitness in patients with relapsed/refractory diffuse large B-cell lymphoma.

Journal: British journal of haematology
Published: January 06, 2023

Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial.

Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial.

Journal: Haematologica
Published: June 24, 2022

Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis.

Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 26, 2022

Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma.

Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma.

Journal: Haematologica
Published: October 12, 2021
Showing 1-12 of 14

Last Updated: 09/26/2026